IMMUNOLOGICAL AND BIOTECHNOLOGICAL STAGES OF ANTITOXIN PRODUCTION AGAINST BOTULISM
Keywords:
Aim. The aim of this review is to analyze the traditional immunological and modern biotechnological stages of antitoxin production against botulism, as well as to highlight existing challenges and promising solutions.Abstract
Introduction. Botulism is a rare but extremely dangerous toxicoinfectious disease caused by botulinum neurotoxins produced by Clostridium botulinum. It is manifested by blurred vision, swallowing and speech disorders, muscle weakness, and descending flaccid paralysis. In severe cases, paralysis of the respiratory muscles leads to acute respiratory failure.
Downloads
References
Zhang S., et al. Botulism: A review of clinical and public health aspects. Toxins. 2021;13(4):275.
Rasetti-Escargueil C., Popoff M. R. Antibodies and vaccines against botulinum toxins: available and prospective strategies. Toxins. 2019;11(9):528.
Centers for Disease Control and Prevention. Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021. MMWR Recommendations and Reports. 2021;70(2):1–30.
Webb R. P., Smith L. A. Development of recombinant antibody-based therapies for botulism. BioDrugs. 2013;27(3):225–236.
Nowakowski A., Wang C., Powers D. B., Amersdorfer P., Smith T. J., Montgomery V. A., Sheridan R., Blake R., Smith L. A., Marks J. D. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proceedings of the National Academy of Sciences of the United States of America. 2002;99(17):11346–11350.
Inglis G. D., et al. Nanobody-based therapeutics for botulism. Microorganisms. 2022;10(8):1637.
Panova E. N., Shcherbakov D. N. Производство и стандартизация противоботулинических сывороток: исторические и современные аспекты. Биофармацевтический журнал. 2023;15(3):12–23.
Rasetti-Escargueil C., et al. Broadly neutralizing nanobodies against botulinum neurotoxin A. Toxins. 2021;13(1):18.
Kalb S. R., et al. Detection of botulinum neurotoxins A, B, E, and F in clinical specimens by mass spectrometry. Analytical Chemistry. 2009;81(13):5613–5620.
Arnon S. S. Creation and development of the human botulism immune globulin intravenous — BIG-IV, BabyBIG®. Pediatrics. 2013;131(5):e1483–e1488.
Kilsby A. J., et al. Immunogenicity of therapeutic equine antisera: clinical implications. Clinical Immunology. 2022;234:108909.
Mukovozova L. A., et al. Immunoprophylaxis of botulism: current status and future directions. Problems of Particularly Dangerous Infections. 2019;1:76–82.
Shcherbakov D. N., et al. Recombinant antibodies to botulinum toxin: generation and preclinical evaluation. Russian Journal of Bioorganic Chemistry. 2020;46(2):195–206.
Sobirova G. N., Axmedova D. R. Bolalarda botulizmning klinik kechishi va davolash tamoyillari. Pediatriya. 2021;2:89–95.
Giyosova N. S. Oziq-ovqat bilan bog‘liq botulizm kasalligining oldini olish va antitoksin terapiyasining ahamiyati. Pediatriya va yuqumli kasalliklar. 2021;3:67–72.
Atabekov I., Talipova M. O‘zbekistonda botulizmning epidemiologik xususiyatlari va profilaktikasi. Infeksion kasalliklar muammolari. 2020;4:23–29.
Abdullaeva M. A., Yusupova N. T. Botulizmga qarshi antitoksin zardobini ishlab chiqarishning biotexnologik usullari. O‘zbekiston farmatsevtik xabarnomasi. 2023;1:34–40.
Karimov X. Ya. Klinik immunologiya va allergologiya. Toshkent: Fan nashriyoti; 2019.
Lévy J., et al. Botulism as a potential bioterrorism agent. Clinical Microbiology and Infection. 2006;12(5):397–404.
Muxammadiev A. A., Kamilov R. S. Botulizm: zamonaviy diagnostika va davolash tamoyillari. O‘zbekiston Tibbiyot Jurnali. 2022;2:45–51.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
